Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripBayer AG has been touting Kerendia (finerenone) as a blockbuster sales product in both kidney and cardiovascular disease for several years, and a July 14 US Food and Drug Administration approval for
Pink SheetWith 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe
ScripBayer has secured the first global approval for elinzanetant, trumpeted as a key growth driver for its pharma division in the coming years, after the UK gave the green light to the hot flashes therapy